Thailand Pharmaceuticals and Healthcare Report Q2 2009

Executive Summary .........5
Thailand Pharmaceutical And Healthcare Industry SWOT ... 6
Thailand Political SWOT................ 7
Thailand Economic SWOT.............. 7
Thailand Business Environment SWOT ....... 8
Pharmaceutical Business Environment Ratings ............9
Table: Asia Pacific Business Environment Rankings For Q209 .................... 9
Limits Of Potential Returns............. 9
Risks To Realisation Of Returns ... 10
Thailand – Market Summary .................11
Regulatory Regime.........12
National Health Assembly Agenda Items ... 12
Intellectual Property Regime ........ 13
IP Shortcomings............... 13
Counterfeit Drugs ............ 14
Compulsory Licensing Regulatory Developments... 15
Recent IP Developments ............... 16
Pricing And Reimbursement ......... 17
Industry Trends And Developments .................18
Epidemiology...... 18
Healthcare System ........... 19
Healthcare Financing...... 20
Medical Tourism.............. 21
Pharmaceutical Sector..... 22
Local Producers............... 23
Foreign Companies.......... 23
Recent Industry Developments...... 25
Traditional Medicines...... 27
Pharmaceutical Retail ..... 27
Vaccine Sector ................. 28
Recent Vaccines Sector Developments....... 29
Research And Development .......... 31
Recent Research And Development Activities......... 32
Biosimilars.......... 33
Clinical Trials..... 34
Medical Devices............... 35
Industry Forecast Scenario ...................36
Overall Market Forecast............... 36
Table: Thailand – Pharmaceutical Market Indicators, 2003-2013 .............. 37
Key Growth Factors – Industry..... 38
Table: Thailand – Healthcare Expenditure Indicators, 2003-2013.............. 39
Key Growth Factors – Macroeconomic ..... 40
Table: Thailand – Economic Activity......... 41
Prescription Market Forecast ....... 42
Table: Thailand – Prescription Market Indicators, Historical Data And Forecast (THBmn unless otherwise indicated) ......... 43
Patented Drug Market Forecasts............... 44
Table: Thailand – Patented Market Indicators, 2003-2013 . 44
Generics Market Forecasts........... 45
Table: Thailand – Generics Market Indicators, 2003-2013. 45
OTC Market Forecast...... 46
Table: Thailand – OTC Market Indicators, 2003-2013 (THBmn unless otherwise indicated) ............ 47
Export/Import Forecasts............... 48
Table: Thailand – Pharmaceutical Trade Indicators, 2003-2013 (US$mn).............. 48
Medical Device Market Forecast............... 49
Table: Thailand – Medical Device Market Indicators,2006-2013 (US$mn unless otherwise stated)............... 49
Other Healthcare Data Forecasts.............. 50
Table: Thailand – Other Health Indicators, 2003-2013....... 50
Key Risks To BMI’s Forecast Scenario...... 51
Competitive Landscape.52
Table: Thailand's Pharmaceutical Market In Q406 (most recent publically available data).............. 52
Company Profiles...........53
Leading Multinational Manufacturers ............ 53
Pfizer .................. 53
Sanofi-Aventis..... 55
Novartis .............. 56
GlaxoSmithKline.............. 58
Merck & Co ........ 60
Domestic Manufacturer Profiles ........ 62
Siam Pharmaceutical....... 62
Government Pharmaceutical Organisation (GPO). 63
Biolab Co............ 67
Thai Meiji Pharmaceutical Co...... 68
Country Snapshot: Thailand Demographic Data ..........69
Section 1: Population ...... 69
Table: Demographic Indicators, 2005-2030........... 69
Table: Rural/Urban Breakdown, 2005-2030 .......... 70
Section 2: Education And Healthcare........ 70
Table: Education, 2002-2005 ....... 70
Table: Vital Statistics, 2005-2030.............. 70
Section 3: Labour Market And Spending Power ..... 71
Table: Employment Indicators, 2001-2006............. 71
Table: Consumer Expenditure, 2000-2012 (US$) ... 71
Table: Average Annual Non-Agricultural Wages, 2001-20 72
BMI Forecast Modelling.73
How We Generate Our Pharmaceutical Industry Forecasts 73
Pharmaceutical Business Environment Ratings Methodology ..................... 74
Ratings Overview............. 74
Table: Pharmaceutical Business Environment Indicators ... 75
Weighting............ 76
Table: Weighting Of Components.............. 76
Sources ....... 76